Tesofensine Results Timeline: What Studies Measured, and When

The short answer: trials reported at scheduled visits, not at "when effects appear"

Questions about how quickly tesofensine "works" cannot be answered from the published record in the way they are usually asked, because clinical trials did not measure the moment an individual noticed a change. They measured pre-specified outcomes at pre-specified visits. For tesofensine, those visits cluster around a handful of timepoints: single-dose pharmacodynamic sessions measured in hours, neurology trials measured over roughly three months, and obesity trials measured at 24 weeks. Everything below describes what researchers reported at those timepoints, in the populations studied, at the doses studied.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision. Nothing here describes a protocol, a schedule or an expected personal result. Background on the molecule, its mechanism and its regulatory status is covered on the tesofensine overview page.

Timeline at a glance: what was measured, and when

Hours to days: what the acute studies captured

The earliest window in the literature is same-day pharmacodynamics. A clinical pharmacology study in recreational stimulant users examined subjective and objective effects of tesofensine, a design built to detect abuse-liability signals in the hours after dosing rather than any weight outcome (PMID 20520602). That study tells readers something about acute central effects and how they were quantified; it does not describe appetite or body-weight trajectories over weeks.

The second early-window question is how long the compound takes to accumulate. Researchers developed and evaluated a quantitative enterohepatic circulation model using tesofensine as one of the test compounds, a modelling exercise aimed at describing plasma concentration behaviour that simple one-compartment assumptions miss (PMID 19705923). The practical implication for reading any timeline is that concentration curves for tesofensine are not instantaneous step functions, so outcomes measured on day 1 and outcomes measured at week 12 reflect different exposure conditions.

Weeks to ~3 months: the neurology programme, where weight change was noticed

Tesofensine, formerly NS 2330, was first developed as a triple monoamine reuptake inhibitor for neurodegenerative disease. A randomized trial of NS 2330 in early Parkinson's disease evaluated motor outcomes and reported that the compound did not meet its primary efficacy endpoint in that population (PMID 17149725). What that programme did generate was an unexpected observation: a pooled analysis of weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease reported dose-related reductions in body weight during those studies (PMID 18356831).

This is an important piece of timeline context. The weight signal was not a designed endpoint measured on a weight-loss visit schedule; it was recorded alongside neurology endpoints and analysed afterwards. Reviews summarising the compound's development history describe this pivot from neurology to obesity as the reason a dedicated obesity trial was run at all (PMID 19777399).

Week 24: the phase 2 obesity endpoint

The most cited timeline anchor is a randomised, double-blind, placebo-controlled trial of tesofensine in obese patients, in which participants completed a 2-week diet run-in before 24 weeks of randomised treatment (PMID 18950853). At the 24-week endpoint, the study reported mean weight loss of 4.5% with 0.25 mg, 9.2% with 0.5 mg and 10.6% with 1.0 mg once daily, compared with 2.0% in the placebo group (PMID 18950853). A secondary publication of the same work described effects on body weight and body composition in obese subjects (PMID 19824222).

Two things follow for anyone reading a "week-by-week" claim. First, the headline percentages are 24-week values, not weekly or monthly values, and the published abstract reports the endpoint rather than a week-by-week curve. Second, the 2-week run-in means every participant had already been on a dietary intervention before randomisation, so the randomised period measured drug effect on top of that background.

Appetite ratings during the same trial

Appetite was studied as a mechanism outcome rather than a weight outcome. Researchers examined the effect of tesofensine on appetite sensations in this obesity population and reported changes in subjective appetite ratings with tesofensine relative to placebo, consistent with an appetite-suppressant mechanism rather than a purely metabolic one (PMID 21720440). Appetite questionnaires are administered at scheduled visits, which is why they appear on the same timeline grid as the weight endpoints rather than describing day-to-day sensations.

Week 24 again: the hypothalamic obesity combination trial

A later randomized controlled trial tested Tesomet — tesofensine combined with metoprolol — for weight loss in hypothalamic obesity, a distinct patient population with weight gain driven by hypothalamic damage (PMID 35294397). The metoprolol component was included specifically to address the cardiovascular signal seen with tesofensine alone, and the trial reported weight and safety outcomes over its randomised treatment period (PMID 35294397). For timeline purposes, this trial matters because it again used a roughly 24-week horizon, reinforcing that the published human evidence base is built around half-year windows and does not extend, in these reports, to multi-year follow-up.

Preclinical timelines (animal data, clearly labeled)

Animal work fills in some shorter-horizon detail that human trials did not publish. In a rat study, researchers reported that anti-hypertensive treatment preserved tesofensine's appetite suppression while preventing its cardiovascular adverse effects (PMID 23784901). Rodent feeding experiments measure intake over days rather than months, so they characterise the onset and persistence of appetite suppression on a much shorter scale than a 24-week clinical visit schedule. These are animal findings and do not translate directly to human timelines, doses or magnitudes.

Cardiovascular and Other Adverse Events: What Studies Report

Adverse events were also tabulated on the trial timeline, not reported as isolated anecdotes. In the 24-week obesity trial, the study reported dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia among the more frequent adverse events, and reported increases in heart rate and blood pressure at the 1.0 mg dose (PMID 18950853). A review of the safety of anti-obesity drugs discussed tesofensine within the broader class context, including the cardiovascular considerations that shaped its regulatory trajectory (PMID 25114779).

Reviews of new and emerging drug molecules against obesity placed tesofensine alongside other investigational agents and summarised where its development stood (PMID 24064009). The rationale for the metoprolol combination is visible in this same context: the hypothalamic obesity trial paired tesofensine with a beta-blocker and reported outcomes for that combination rather than for tesofensine alone (PMID 35294397).

Where the published timeline is thin or absent

Several timeline questions cannot be answered from the verified literature summarised here, and it is more useful to say so than to interpolate:

• Week-by-week weight curves. The obesity trial abstract reported 24-week mean weight loss by dose group (PMID 18950853); intermediate weekly values are not something this page can attribute to it.
• Time to first measurable appetite change. Appetite sensations were studied and reported within the obesity trial population (PMID 21720440), but a specific "day X" onset threshold is not something the abstract establishes.
• Beyond six months. The randomised human reports summarised here — including the hypothalamic obesity trial (PMID 35294397) — describe treatment periods on the order of months, not years, so durability and post-treatment regain are not characterised in this citation set.
• Non-clinical use. No study in this set evaluated tesofensine outside a supervised research or trial setting, and reviews of anti-obesity drug safety discuss it as an investigational agent (PMID 25114779).

Reading timeline claims critically

Three habits help when evaluating any claim about how fast a compound "works":

1. Check the population. Weight loss reported in patients with Parkinson's or Alzheimer's disease (PMID 18356831) came from a different population and study design than weight loss reported in obese participants over 24 weeks (PMID 18950853).
2. Check whether the endpoint was designed or incidental. A randomized trial in early Parkinson's disease was designed around motor endpoints, not weight (PMID 17149725).
3. Check the exposure window. Pharmacokinetic modelling of enterohepatic recirculation shows why acute and chronic exposure conditions differ (PMID 19705923), which is part of why an acute subjective-effects study (PMID 20520602) and a 24-week weight trial are not measuring the same thing.

In summary, the published tesofensine timeline is a grid of scheduled measurements: acute pharmacodynamic sessions, development-programme endpoints in neurology populations where weight change was reported as a secondary observation (PMID 18356831), and 24-week obesity endpoints where researchers reported dose-related mean weight loss versus placebo (PMID 18950853). Anything finer-grained than that is interpretation, not data.

References

• Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (Lancet, 2008)
• Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease (Obesity, 2008)
• Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease (Movement Disorders, 2007)
• The effect of tesofensine on appetite sensations (Obesity, 2012)
• The effect of tesofensine on body weight and body composition in obese subjects--secondary publication (Ugeskrift for Laeger, 2009)
• Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity (European Journal of Endocrinology, 2022)
• Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users (Clinical Pharmacology and Therapeutics, 2010)
• A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam (Clinical Pharmacokinetics, 2009)
• Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats (Obesity, 2013)
• Safety of antiobesity drugs (Therapeutic Advances in Drug Safety, 2013)
• Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity (Current Opinion in Investigational Drugs, 2009)
• New and emerging drug molecules against obesity (Journal of Cardiovascular Pharmacology and Therapeutics, 2014)